• home rotate text1
  • home rotate text2
  • home rotate text3

NeoChord, Inc.

A venture backed medical device company, is investigating minimally invasive technology intended to transform the treatment of mitral regurgitation.  The company has an exclusive worldwide license to the technology and is currently working on additional minimally invasive technologies for the treatment of structural heart disease.
-Learn More-

Latest Developments and Events

  • NeoChord Appoints Lori Adels, Ph.D. as Vice President of Clinical, Regulatory and Quality; 
    October 20, 2015
    -Click for Release -

  • NeoChord Crosses 250th Patient Milestone! 
    June 30, 2015

  • NeoChord Secures $20 Million Series C Financing; 
    June 9, 2015
    - Click for Release -

What The Experts Are Saying

"NeoChord is setting a new standard for minimally invasive mitral valve repair, and at our institution has become the first-line treatment option for degenerative mitral valve regurgitation."  

-Professor Gino Gerosa, University of Padova Medical School, Italy.

- Click to Learn More -